Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy

Radiology and Oncology

Mitja Lainscak¹  Daniel Omersa²  Tanja Cufer³  Robert Marcun⁴ 

[1] Corresponding authorFaculty of Medicine, Ljubljana, SloveniaDepartments of Cardiology and Research and Education, General Hospital Celje, Celje, Slovenia;National Institute of Public Health, Ljubljana, SloveniaOther articles by this author:;University Clinic Golnik, Golnik, SloveniaFaculty of Medicine, Ljubljana, SloveniaOther articles by this author:;University Clinic Golnik, Golnik, SloveniaOther articles by this author:

关键词: cardiotoxicity;    platinum-based chemotherapy;    lung cancer;    cardiac biomarkers;   

DOI  :  10.1515/raon-2016-0037

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundNon-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains an important cause of cancer death worldwide. Platinum-based chemotherapy (PBC) for NSCLC can modify outcome while the risk of cardiotoxicity remains poorly researched. We aimed to evaluate the incidence and severity of cardiac injury during PBC in patients with NSCLC and to identify patients at risk.

【 授权许可】

Unknown